ASCO 2022 Conference Coverage


 

ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolimab + Pembro + Etoposide/Platinum vs. Atezo + EP in ES-SCLC

510 views
June 9, 2022
Comments 0
Login to view comments. Click here to Login